• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Educated Patient® Breast Cancer Summit at MBCC Keynote Presentation: March 4, 2023

Video

Watch Dr. Anne O'Dea, from University of Kansas Medical Center, discuss targeting ESR1 mutations during the CURE Educated Patient® Breast Cancer Summit at MBCC.

At the CURE Educated Patient® Breast Cancer Summit, held live and virtually at the Miami Breast Cancer Conference, Dr. Anne O'Dea, medical director of breast cancer survivorship at the University of Kansas Medical Center, presented the keynote lecture, titled “A new era in the treatment of ER+, HER2- Advanced or Metastatic Breast Cancer: targeting ESR1 mutations.”

Educated Patient® Breast Cancer Summit at MBCC

Educated Patient® Breast Cancer Summit at the Miami Breast Cancer Conference, held March 4, 2023.

In particular, O’Dea discusses the need for new endocrine therapies to treat estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as well as results from the EMERAL trial, that led to the Food and Drug Administration approval of elacestrant (Orserdu) in this patient population.

Disclosure: O’Dea is a consultant and/or speaker for Gilead, DSI, Puma, Pfizer, Novartis and Stemline.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content